Article
Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines.
Cell reports - 27 Aug 2024
Huber Anne, Allam Amr H, Dijkstra Christine, Thiem Stefan, Huynh Jennifer, Poh Ashleigh R, Konecnik Joshua, Jacob Saumya P, Busuttil Rita, Liao Yang, Chisanga David, Shi Wei, Alorro Mariah G, Forrow Stephen, Tauriello Daniele V F, Batlle Eduard, Boussioutas Alex, Williams David S, Buchert Michael, Ernst Matthias, Eissmann Moritz F
Abstract excerpt
Although aberrant activation of the KRAS and PI3K pathway alongside TP53 mutations account for frequent aberrations in human gastric cancers, neither the sequence nor the individual contributions of these mutations have been clarified. Here, we establish an allelic series of mice to afford conditional expression in the glandular epithelium of KrasG12D;Pik3caH1047R or Trp53R172H and/or ablation of Pten or Trp53....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.